To include your compound in the COVID-19 Resource Center, submit it here.

Zynerba gains on fragile X syndrome data

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) jumped $3.25 (53%) to $9.44 on Thursday after reporting that its synthetic cannabidiol (CBD) gel ZYN002 met

Read the full 210 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE